BioSpace News Archive

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as a potential treatment for Friedreich’s ataxia will be featured in two upcoming poster presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress.

Umoja Biopharma, Inc. announced data from three presentations at the American Society of Gene and Cell Therapy Annual Meeting on its scalable, off-the-shelf in vivo lentiviral vector-based platform, termed VivoVec, that has the potential to achieve efficient T cell transduction upon direct administration to patients.

Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announced titles of nine abstracts to be presented as oral presentations and posters at the International Society for Extracellular Vesicles (ISEV) Annual Meeting, on May 25 to 29, 2022, in Lyon, France.

Enlivex Therapeutics Ltd. announced that company management will present a corporate overview and participate in virtual one-on-one investor meetings during the H.C. Wainwright Global Investment Conference, which is taking place from May 23 – 26, 2022.

4C Medical Technologies, Inc. presented its global clinical experience from its initial AltaValve Early Feasibility Study cases at the American Association for Thoracic Surgery 2022 Mitral Conclave Workshop on May 13, 2022 in Boston, MA.

Myeloid Therapeutics, Inc. (“Myeloid” or the “Company”), today announced that it has entered into an agreement with Acuitas Therapeutics (“Acuitas”), a global leader in developing LNP delivery systems that enable mRNA-based therapeutics.

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, is further growing its global production capacity with the expansion of its manufacturing site in Tunisia.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, and Lonza announced today the opening of a new, custom-built, bioconjugation facility within Lonza’s Ibex® Dedicate manufacturing complex in Visp (CH).

Moleculin to Present at the H.C. Wainwright Global Investment Conference.

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host an inaugural virtual Investor Day on June 6, 2022, at 10:00 a.m. – 12:30 p.m. ET.